Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

RBCC Explores New Funding for Expansion



  RBCC Explores New Funding for Expansion

Business Wire

NOKOMIS, Fla. -- June 10, 2013

As Rainbow Coral Corp. (OTCBB: RBCC) pushes forward with its aggressive
expansion strategy for 2013, the company is considering promising new funding
opportunities in order to deliver cutting-edge innovations to the $232 billion
personalized medicine market.

RBCC is already poised for rapid growth this year. The company recently signed
a joint venture agreement with TheraKine Ltd., the developer of a
revolutionary, sustained-release drug delivery platform that could soon make
local delivery of biologic agents and small molecules safer, more effective
and more convenient than ever before, and is currently in negotiations to
partner with an emerging innovator in the transdermal delivery sector, as
well. Last month, RBCC’s joint venture partner, Nano3D BioSciences, announced
a distribution agreement with St. Louis-based scientific products distributor
MIDSCI to sell its revolutionary BioAssembler product line in the
multi-billion-dollar U.S biotechnology market.

To continue expanding its marketing and development efforts, RBCC will explore
new funding opportunities in order to capitalize on the unprecedented rise of
the biotechnology sector.

“Our company is now well-positioned in a robust marketplace, and new funding
opportunities are opening up for us every day,” said RBCC CEO Patrick Brown.
“We’re carefully considering our options in order to ensure that we’re able to
accomplish the goals that we’ve set for ourselves this year.”

For more information on RBCC’s partnership with n3D and other biotech
initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT)
and Amgen Inc. (NASDAQ: AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB: RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
info@rainbowcoral.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement